Gene Expression Biomarkers for Epilepsy: Identification Through Novel Integrative Evidence-Based Genomics Analysis
Abstract number :
1.493
Submission category :
2. Translational Research / 2C. Biomarkers
Year :
2025
Submission ID :
1247
Source :
www.aesnet.org
Presentation date :
12/6/2025 12:00:00 AM
Published date :
Authors :
Presenting Author: Vishruth Nagam, MMCi, BS – Duke University School of Medicine; University of California, Riverside School of Medicine
Rationale: Epilepsy affects approximately 50 million individuals globally, manifesting as seizures without identifiable medical causes. Differentially expressed genes are valuable candidate biomarkers to facilitate early detection and diagnosis of epilepsy via genetic tests. This work represents research to identify such biomarkers for epilepsy.
Methods: This study performs neuroinformatics research and integrative evidence-based genomics analyses to analyze differential gene expression in epilepsy, utilizing large-scale gene expression data from the blood transcriptome, and identify a consistent gene expression profile for epilepsy. This research represents a novel blood “omics” informatics approach to epilepsy.
Results: This research represents a novel blood “omics” informatics approach to epilepsy. A consistent gene expression profile and novel biomarkers were identified for epilepsy from the blood platelet transcriptome. The strongest biomarkers for epilepsy are identified as the CD163, SLC25A39, SH3BP5L, SOCS1, and IRAK3 genes.
Conclusions: These findings enhance our understanding of the molecular mechanisms underlying epilepsy and contribute to the development of precision health solutions, such as genetic tests, that could expedite diagnosis and treatment of epilepsy.
Funding: The University of California, Riverside Honors Excellence in Research (HEIR) Scholarship was received as this work was being completed.
Translational Research